Clinical Trial Update: A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This is a Phase 1 study evaluating CGT6297, a mutant-selective inhibitor, in adults with advanced solid tumors, including PIK3CA-mutant endometrial cancer and c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Hormone Receptor-positive Breast Cancer
• Low Breast Cancer
• Solid Tumors

Drugs mentioned

• CGT6297

Snippet

Sponsor: Cogent Biosciences, Inc. | Conditions: PIK3CA Mutations, Advanced Solid Tumors, Adult | Phase 1 | Status: NOT_YET_RECRUITING